Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grazoprevir/Elbasvir for HCV+ to HCV- Kidney Transplant
NCT02945150Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2017
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of grazoprevir in hepatitis C (HCV), sponsored by Massachusetts General Hospital. Primary endpoint: Undetectable HCV RNA at SVR12. Started Feb 2017; status: completed.
02
Drugs
grazoprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02945150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02945150.